Elixiron Immunotherapeutics
PublicLast Round
Series B
Jun 12, 2025
Total Funding Raised
$70M
Company Overview
Elixiron Immunotherapeutics is a clinical-stage biotechnology company that develops precision immunotherapies for neuroinflammatory diseases, autoimmune diseases, and cancer.
AI Layer
Application
Keywords
immunotherapydrug discoverytherapeutic vaccinemonoclonal antibodybiotechoncologyinflammatory diseaseai drug discoveryclinical-stage biotechbiopharmaprecision medicinedrug licensingin silico drug designmulti-omics
Elixiron Immunotherapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Elixiron Immunotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 12, 2025 | ||||
| Grant | Jul 12, 2022 | ||||
| Series A Extension | Aug 23, 2021 | ||||
| Grant | Aug 25, 2020 | ||||
| Series A | Jul 31, 2019 |
Key People
Founding team and executive leadership
Elixiron Immunotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Taiwania Capital | Series A, Series A Extension |
| Fubon Financial Holding Venture Capital | Series A Extension |
| CDIB Capital International | Series A |
| China Investment & Development Company, Limited | Series A Extension |
| Alzheimer's Association | Grant |
| Fubon Financial Holdings | Series A Extension |
Elixiron Immunotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
Headquarters—
Employee Range23
Year Founded2017
Last FundingJun 12, 2025